Literature DB >> 1773959

Dysplasia and carcinoma in longstanding ulcerative colitis: an endoscopic and histological surveillance programme.

M Leidenius1, I Kellokumpu, A Husa, M Riihelä, P Sipponen.   

Abstract

From 1976 to 1989 a total of 66 patients with longstanding ulcerative colitis were entered in a colonoscopic surveillance programme in order to detect dysplasia. Thirty patients had extensive or total ulcerative colitis and 36 left sided colitis. The median duration of the disease at the end of the follow up was 15.0 years. Altogether 182 colonoscopies (2.8 per patient), each involving approximately 20 biopsies from different sites of the colon, were performed. In the total or extensive colitis group, five patients had low grade and one patient had high grade dysplasia. In the left sided colitis group, three patients had low grade dysplasia. In three patients low grade dysplasia was detected in a macroscopic lesion or mass of colonic mucosa. Sixty per cent of the dysplasia specimens were from the right colon. The incidence of dysplasia was higher in patients with extensive colitis and increased with the duration of the disease. None of the patients have so far developed colorectal carcinoma. Our results indicate that a colonoscopic surveillance programme is a safe alternative to prophylactic colectomy in longstanding ulcerative colitis.

Entities:  

Mesh:

Year:  1991        PMID: 1773959      PMCID: PMC1379254          DOI: 10.1136/gut.32.12.1521

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

1.  THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. III. COMPLICATIONS.

Authors:  F C EDWARDS; S C TRUELOVE
Journal:  Gut       Date:  1964-02       Impact factor: 23.059

2.  Ulcerative colitis. Cancer surveillance in an unselected population.

Authors:  J Rutegård; L Ahsgren; R Stenling; K G Janunger
Journal:  Scand J Gastroenterol       Date:  1988-03       Impact factor: 2.423

Review 3.  Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review.

Authors:  R H Collins; M Feldman; J S Fordtran
Journal:  N Engl J Med       Date:  1987-06-25       Impact factor: 91.245

4.  Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres.

Authors:  S N Gyde; P Prior; R N Allan; A Stevens; D P Jewell; S C Truelove; R Lofberg; O Brostrom; G Hellers
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

5.  Rectal biopsy as an aid to cancer control in ulcerative colitis.

Authors:  B C Morson; L S Pang
Journal:  Gut       Date:  1967-10       Impact factor: 23.059

6.  Surveillance for colonic carcinoma in ulcerative colitis.

Authors:  E Rosenstock; R G Farmer; R Petras; M V Sivak; G B Rankin; B H Sullivan
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682

7.  Cancer surveillance of patients with longstanding ulcerative colitis: a clinical, endoscopical, and histological study.

Authors:  O Broström; R Löfberg; A Ost; H Reichard
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

8.  Screening by colonoscopy for colonic epithelial dysplasia in inflammatory bowel disease.

Authors:  A P Manning; O R Bulgim; M F Dixon; A T Axon
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

9.  Cancer surveillance in ulcerative colitis. Experience over 15 years.

Authors:  J E Lennard-Jones; B C Morson; J K Ritchie; C B Williams
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

10.  Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program.

Authors:  B A Lashner; M D Silverstein; S B Hanauer
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

View more
  15 in total

1.  Ten year follow up of ulcerative colitis patients with and without low grade dysplasia.

Authors:  C H Lim; M F Dixon; A Vail; D Forman; D A F Lynch; A T R Axon
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 2.  Dysplasia and colitis.

Authors:  Robert Enns; Brian Bressler
Journal:  Can J Gastroenterol       Date:  2009-05       Impact factor: 3.522

Review 3.  How reliable/valid is dysplasia in identifying at-risk patients with ulcerative colitis?

Authors:  R H Riddell
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 4.  How do we assess the value of surveillance techniques in ulcerative colitis?

Authors:  C N Bernstein
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

5.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 6.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

Review 7.  Cancer surveillance in ulcerative colitis--a time for reappraisal.

Authors:  A T Axon
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

8.  In-vivo characterization of DALM in ulcerative colitis with high-resolution probe-based confocal laser endomicroscopy.

Authors:  Giovanni D De Palma; Stefania Staibano; Saverio Siciliano; Francesco Maione; Maria Siano; Dario Esposito; Giovanni Persico
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

9.  Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines.

Authors:  Timothy L Zisman; Mary P Bronner; Stephen Rulyak; Kris V Kowdley; Michael Saunders; Scott D Lee; Cynthia Ko; Michael B Kimmey; Allyn Stevens; Josephine Maurer; Teresa A Brentnall
Journal:  Inflamm Bowel Dis       Date:  2012-04-16       Impact factor: 5.325

Review 10.  Failure of colonoscopic surveillance in ulcerative colitis.

Authors:  D A Lynch; A J Lobo; G M Sobala; M F Dixon; A T Axon
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.